Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™
April 05 2017 - 7:30AM
Business Wire
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced
that it will present clinical data on ARC-520, ARC-521, and
ARC-AAT, the company’s prior generation investigational medicines
that were being studied for the treatment of chronic hepatitis B
infection and liver disease associated with alpha-1 antitrypsin
deficiency, at The International Liver Congress™ 2017 (ILC), the
annual meeting of the European Association for the Study of the
Liver (EASL) being held in Amsterdam, the Netherlands from April
19-23, 2017.
Oral Presentations:
Prolonged RNA interference therapy with ARC-520 Injection in
treatment naïve, HBeAg positive and negative patients with chronic
HBV results in significant reductions of HBs antigen
- Presentation Reference: PS-045
- Session: Parallel session: Hepatitis B
and D: Emerging treatment options
- Date and Time: April 20, 2017 at 5:30
PM CET
- Authors: Man-Fung Yuen, et al.
Hepatic targeted RNA interference provides deep and prolonged
knockdown of alpha-1 antitrypsin levels in ZZ patients
- Presentation Reference: LBO-06
- Session: Late Breaker session
- Date and Time: April 22, 2017 at 5:15
PM CET
- Authors: Alice Turner, et al.
Poster Presentation:
A phase 1 study to evaluate safety and tolerability of
escalating single doses of the HBV RNA interference drug ARC-521 in
a healthy volunteer population
- Presentation Reference: THU-176
- Session: Viral hepatitis: Hepatitis B
and D - Clinical (therapy, new compounds, resistance)
- Session Date and Time: April 20, 2017
from 8:00 AM to 6:00 PM CET
- Authors: Edward Gane, et al.
Additional details including presentation abstracts can be found
on the ILC website at https://ilc-congress.eu/. A copy of
presentation materials can be accessed by visiting the Events
section of the Arrowhead website after the presentations
conclude.
Arrowhead announced on November 29, 2016 that it had
discontinued development of ARC-520, ARC-521, and ARC-AAT. The
company continues to develop ARO-HBV and ARO-AAT, which are follow
on investigational RNAi therapeutics against chronic hepatitis B
infection and alpha-1 liver disease that utilize the company’s new
proprietary subcutaneous delivery system.
The International Liver Congress is a trademark of the European
Association for the Study of the Liver.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat
intractable diseases by silencing the genes that cause them. Using
a broad portfolio of RNA chemistries and efficient modes of
delivery, Arrowhead therapies trigger the RNA interference
mechanism to induce rapid, deep, and durable knockdown of target
genes. RNA interference, or RNAi, is a mechanism present in living
cells that inhibits the expression of a specific gene, thereby
affecting the production of a specific protein. Arrowhead’s
RNAi-based therapeutics leverage this natural pathway of gene
silencing.
For more information, please visit www.arrowheadpharma.com, or
follow us on Twitter @ArrowheadPharma. To be added to the Company's
email list and receive news directly, please visit
http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including the safety and efficacy of our
product candidates, the duration and impact of regulatory delays in
our clinical programs, our ability to finance our operations, the
future success of our scientific studies, our ability to
successfully develop drug candidates, the timing for starting and
completing clinical trials, rapid technological change in our
markets, and the enforcement of our intellectual property rights.
Our most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q discuss some of the important risk factors
that may affect our business, results of operations and financial
condition. We assume no obligation to update or revise
forward-looking statements to reflect new events or
circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170405005323/en/
Arrowhead Pharmaceuticals, Inc.Vince Anzalone,
CFA626-304-3400ir@arrowheadpharma.comorInvestor
Relations:The Trout GroupChad Rubin,
646-378-2947ir@arrowheadpharma.comorMedia:Russo PartnersRich
Allan, 646-942-5588rich.allan@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024